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Abstract
Background: Pneumonia is a leading cause of children’s deaths in developing countries and hinders achievement
of the fourth Millennium Development Goal. This goal aims to reduce the under-five mortality rate, by two thirds,
between 1990 and 2015.
Few studies have examined the impact of zinc adjunct therapy on the outcome of childhood pneumonia. We
determined the effect of zinc as adjunct therapy on time to normalization of respiratory rate, temperature and
oxygen saturation. We also studied the effect of zinc adjunct therapy on case fatality of severe childhood
pneumonia (as a secondary outcome) in Mulago Hospital, Uganda.
Methods: In this double blind, randomized, placebo-controlled clinical trial, 352 children aged 6 to 59 months,
with severe pneumonia were randomized to zinc (20 mg for children ≥12 months, and 10 mg for those < 12
months) or a placebo once daily for seven days, in addition to standard antibiotics for severe pneumonia. Children
were assessed every six hours. Oxygen saturation was normal if it was above 92% (breathing room air) for more
than 15 minutes. The respiratory rate was normal if it was consistently (more than 24 hours) below 50 breaths per
minute in infants and 40 breaths per minute in children above 12 months of age. Temperature was normal if
consistently below 37.5°C. The difference in case fatality was expressed by the risk ratio between the two groups.
Results: Time to normalization of the respiratory rate, temperature and oxygen saturation was not significantly
different between the two arms.
Case fatality was 7/176 (4.0%) in the zinc group and 21/176 (11.9%) in the placebo group: Relative Risk 0.33 (95% CI
0.15 to 0.76). Relative Risk Reduction was 0.67 (95% CI 0.24 to 0.85), while the number needed to treat was 13.
Among HIV infected children, case fatality was higher in the placebo (7/27) than in the zinc (0/28) group; RR 0.1
(95% CI 0.0, 1.0).
Among 127 HIV uninfected children receiving the placebo, case fatality was 7/127 (5.5%); versus 5/129 (3.9%)
among HIV uninfected group receiving zinc: RR 0.7 (95% CI 0.2, 2.2). The excess risk of death attributable to the
placebo arm (Absolute Risk Reduction or ARR) was 8/100 (95% CI: 2/100, 14/100) children. This excess risk was
substantially greater among HIV positive children than in HIV negative children (ARR: 26 (95% CI: 9, 42) per 100
versus 2 (95% CI: -4, 7) per 100); P-value for homogeneity of risk differences = 0.006.
Conclusion: Zinc adjunct therapy for severe pneumonia had no significant effect on time to normalization of the
respiratory rate, temperature and oxygen saturation. However, zinc supplementation in these children significantly
decreased case fatality.
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Background
Acute respiratory tract infections are the most common
cause of morbidity and deaths in children less than five
years. They account for 10 to 30% of all childhood
deaths and are thus a hindrance to attaining the fourth
Millennium Development Goal [1]. The burden of acute
lower respiratory tract infections is 2 to 10 times more
common in developing than in developed countries [2].
Zinc deficiency is a global problem affecting popula-
tions of low socioeconomic status in both developing and
developed countries [3]. Populations in South-East Asia
and sub-Saharan Africa are at greatest risk because zinc
intakes are inadequate for about one-third of the popula-
tion [4]. In addition, zinc is the most deficient nutrient in
complementary foods fed to infants during weaning [5].
The prevalence of zinc deficiency in Uganda ranges from
20 to 69% in children and 21 to 29% in adults [6,7].
One randomized controlled study from Bangladesh
showed that zinc adjunct therapy accelerated recovery
of children with severe pneumonia [8], but other studies
have shown no effect [9,10]. Hitherto, no studies have
assessed the impact of zinc adjunct therapy on case
fatality of children with pneumonia.
The main objectives of our study were to establish
time taken for normalization of respiratory rate, time
taken for normalization of temperature, and time taken
for oxygen saturation to normalize. The secondary
objective was to determine the effect of zinc adjunct
therapy on case fatality of severe childhood pneumonia
in children aged 6 to 59 months at Mulago Hospital in
Uganda. The major and very interesting finding from
this study (that is, the effect of zinc adjunct therapy on
severe pneumonia case fatality) comes from the second-
ary objective and not from any of the primary ones.
Methods
Study design and setting
This was a randomized double blind placebo-controlled
clinical trial. The study was conducted in one pediatric
ward at Mulago, Uganda’s teaching and national referral
hospital. It receives patients from the capital city, Kam-
pala, and referrals from the rest of the country.
Outcome measures
The primary outcome measures were the time taken for
normalization of respiratory rate, time taken for
normalization of temperature and time taken for oxygen
saturation to normalize (92% or more), while breathing
room air. The oxygen saturation cut off was set at 92%
according to a study in the same hospital by Tumwesi-
gye [11]. The secondary outcome measure was the pro-
portion of children who died in each arm of the study.
Adverse effects due to zinc adjunct therapy, such as
diarrhea and vomiting, were recorded. All children were
observed for adverse events for one hour after zinc
administration. The caretakers were subsequently asked
(daily) about adverse events, such as vomiting.
Definitions
Severe pneumonia was defined as the presence of cough
or difficult breathing with fast breathing (tachypnoea)
and chest in-drawing. Tachypnoea was defined as a
respiratory rate of 50 or more breaths per minute in a
child 6 to 12 months of age. For those aged 12 or more
months it was defined as 40 or more breaths per min-
ute. In any case, the child had to be calm. Normalization
of oxygen saturation was regarded as oxygen saturation
above 92% while breathing room air for more than 15
minutes, and maintaining above 92% on subsequent
readings. Children, who were not hypoxic on enrolment,
were assigned ‘zero’ as the time to normalization of oxy-
gen saturation.
The respiratory rate was regarded as normal if it was
consistently below 50 breaths per minute in infants and
40 breaths per minute in children above 12 months of
age for more than 24 hours. Temperature was recorded
as normal if below 37.5°C and maintained below this
level for more than 24 hours. Two investigators agreed
on the presence of lower chest retractions or chest in-
drawing. If they disagreed, a third investigator was called
to observe and decide whether chest in-drawing was
present. When two of the three agreed, then the deci-
sion was that chest in-drawing was present.
Sample size
For time to normalization of the respiratory rate, a sam-
ple size of 313 was calculated. We assumed 90% power,
a two-sided 0.05 type I error and a hazard ratio of 1.49.
We assumed a median time to normalization of respira-
tory rate of 73 hours (based on an Indian study) [9].
Allowing for 10% attrition, the minimum total sample
size was 344.
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ple size of 312 was calculated. We assumed 90% power,
a two-sided 0.05 type I error and hazard ratio of 1.49;
and a median time to normalization of the temperature
of 72.3 hours (based on the same Indian study) [9].
Allowing for 10% attrition the minimum sample size
was 343. The sample size for time to normalization of
oxygen saturation was similar to that of time to normal-
ization of the temperature. For case fatality as a second-
ary outcome, the minimum sample size of 378 (189 in
each group) was based on 20% case fatality in children
admitted with severe pneumonia to Mulago Hospital
[12]. We assumed that zinc supplementation would
r e d u c et h ec a s ef a t a l i t yf r o m2 0 %t o9 . 3 %w i t h8 0 %
power and a type 1 error of 0.05. Allowing for 10% attri-
tion, the minimum total sample size would be 416 (208
in each group).
Participants and recruitment
We enrolled children, aged 6 to 59 months, who were
admitted to the Mulago Hospital pediatric emergency
ward with severe pneumonia, and whose parents or
caretakers gave informed written consent. The children
were followed up for one week. The definition of severe
pneumonia was based on WHO criteria [13].
Children with known heart conditions, obstructive air
way disease and those on medication with zinc supple-
ments were excluded. Children with a current episode of
wheeze were also excluded, irrespective of previous wheez-
ing attacks. The exclusions were based on caretaker his-
tory, physical examination findings and previous medical
records. Heart disease was defined as the presence of
tachypnoea associated with a grade 3 or 4 heart murmur
or medical records confirming heart disease. Obstructive
airway disease was defined as recurrent wheezing attacks
associated with tachypnoea or chest in-drawing confirmed
on two or more previous examinations by medical records.
Current treatment with zinc was confirmed by reviewing
medical records.
For all enrolled children, two of us (MGS and CKM)
took a detailed history and clinical examination.
A pulse-oximeter (model Ohmeda Biox 3700 Ohmeda
(GE Healthcare), Pollards Wood Chalfont St. Giles,
Bucks HP8 4SP United Kingdom.) with an in-built auto-
matic calibration was used to measure oxygen satura-
tion. Blood smears for malarial parasites and HIV
serostatus of the children were also assessed. Additional
consent was sought for HIV testing. Only 311/352 or
(88.4%) consented to HIV testing.
Randomization, blinding and treatment allocation
Eligible children were enrolled in serial order and ran-
domized to receive either oral zinc or placebo.
The zinc and placebo tablets were packaged and labeled
with study identification numbers by a pharmacist not
directly involved in the care of the patients. Macleod Phar-
maceutical Ltd, Mumbai, India, manufactured the zinc and
placebo tablets. Both zinc and placebo tablets were similar
in color, shape and size. The investigators, study nurses
and parents/caretakers were masked to the treatment and
only the pharmacist had access to the study code. On
receiving an eligible child, the study physicians informed
one of the investigators (pediatrician) who in turn
informed the pharmacist who had access to the randomi-
zation code. The pharmacist then prepared the dose of
zinc/placebo according to the age of the participant. He
packaged the zinc or placebo in a sealed opaque envelope,
which he labeled with the study identification number.
The envelopes were then delivered to one of the investi-
gators’ offices from where the nurse took them to the
ward. The nurse gave treatment according to the envel-
opes. Zinc/placebo administration was directly supervised
by the nurse within 30 minutes after giving antibiotics.
Intervention
Children less than 12 months received 10 mg of zinc (as
zinc gluconate) or the placebo while those aged 12 months
or more received 20 mg of zinc or placebo once daily for
seven days as we anticipated children with pneumonia to
have recovered [14] by Day 7. Dosing was closely related
to the recommended dietary allowance (RDA) of zinc [15].
The water soluble tablets were crushed into powder and
placed into the mouth of those children who could not
take them directly. If vomiting occurred within half an
hour, the dose was repeated.
Laboratory and radiological investigations
Blood for full blood count and HIV serology was taken by
venipuncture from the cubital fossa or dorsum of the hand
in 5 ml EDTA vacutainer tubes (Becton Dickinson, Frank-
lin Lakes, NJ, USA). HIV sero-status of study patients
below 18 months of age was confirmed using DNA PCR.
Blood for serum zinc was collected using trace element-
free vacutainers (Becton Dickinson) and storage tubes.
Just before the zinc assays were carried out, we diluted
the serum samples five-fold using de-ionized water
according to the manufacturer of the test kit [16]. Col-
orimetric zinc determination was done using a Quanti-
chrom™ zinc assay kit (BioAssay Systems · 3191
Corporate Place, Hayward, CA 94545, USA). In this
assay, serum zinc reacts with a chromogen to give a
colored complex whose color intensity is directly pro-
portional to the zinc concentration read at 425 nm.
Internal control was used, using pooled serum and every
batch produced a value of 45.2 ± 4.5 μg/dL. Unfortu-
nately, no external controls were available.
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sample and sample Blank (50 μL sample + 2 μLE D T A )
into wells of a clear bottom 96-well plate according to
the manufacturer’s manual [16]. We then added 200 μL
working reagent, tapping the plate gently in order to
mix. This was incubated for 30 minutes at room tem-
perature and the optical density was read at 420 to 426
nm (peak absorbance at 425 nm).
The concentration of zinc was then calculated using
the following equation:
ODSAMPLE − ODBLANK, ×10 × n(micromoles)/ODSTANDARD − ODWATER
OD is the optical density at 425 nm. Where n is the
dilution factor (n = 5 for serum or plasma samples).
The conversion was ‘’1 μM zinc equals 6.5 μg/dL.’’
Treatment of participants
Children received either intravenous chloramphenicol
[Ciron Drugs &Pharceuticals Ltd, MIDC, Tarapur Boo-
sar Thane India] 25 mg/kg every six hours or ceftriax-
one [Hoffmann Roche Ltd Basel, Switzerland] 75 mg/kg
once daily for seven days. Second line antibiotics: genta-
micin (2.5 mg/kg every 12 h) and cloxacilin [Flamingo
Pharmaceuticals Ltd, Indus, India]. (50 mg/kg every 6 h)
were only given if there was no response after two days
of treatment. On enrolment, 50/352 (14.2%) children
were unable to feed orally and fed by naso-gastric tube
on milk, porridge and locally available soups. Children
with a peripheral oxygen saturation of less than 92%
were given oxygen by nasal prongs or catheter.
For patients on oxygen, we disconnected the oxygen
supply for five minutes before the oxygen saturation was
measured. We counted respirations using a timer for 60
seconds when the chest and abdomen were exposed
according to WHO Integrated Management of Child-
hood Illness (IMCI) guidelines [13]. The count was
repeated and the average was taken as the true value if
the difference between the two counts was not more
than five breaths per minute. If the difference was more
than five breaths per minute, a third count was done
and the average of the closest two respiratory rates was
taken as the true value.
The study team was comprised of three doctors and
two nurses (clinic team) and two laboratory personnel.
The clinic team had prior experience in assessing and
managing children with severe pneumonia. They were
trained on the study procedures and assessment of clini-
cal signs before commencement of the study to ensure
reproducibility and consistency.
A three-member independent team was comprised of
a pediatrician, an epidemiologist and a pharmacist, who
regularly and closely monitored the data. Interim analy-
sis was done when we had accrued half the sample size.
All children received vitamin A as part of treatment for
pneumonia as recommended by WHO [13]. Fluid ther-
apy was given according to hydration status.
Follow-up
All children were followed up until discharge, death or a
maximum of seven days, whichever came first. Patients
were reviewed every six hours for the first 48 hours and
then every 12 hours. The clinical review included the
respiratory rate, presence of chest in-drawing, oxygen
saturation, auscultation findings, fever, cyanosis and
mental state. All children were monitored for vomiting
and diarrhea using information from the caretaker or by
observation. Criteria for discharge included: resolution
of fever, persistently normal respiratory rate, and oxygen
saturation for more than 48 hours and disappearance of
chest in-drawing.
Data management and analysis
￿ All the data were double-entered into the EPI-
INFO 6.04 computer software package (Center for
Disease Control and Prevention, Atlanta, Georgia,
USAand analyzed using SPSS(SPSS Inc., Chicago Ill.)
= and Stata version 9.2 (StataCorp LP, College Station,
TX, USA). Analysis was by intention to treat. The Stu-
dent’s t-test was used for comparing normally distributed
continuous data, and the Mann Whitney test for skewed
continuous data. The Chi square or Fisher’s exact test
(where appropriate) was used to assess differences in
categorical data between the zinc and placebo arms. Each
child’s observation started on enrolment and ended on
D a y7o re a r l i e r ,a tt h et i m eo fd e a t hf o rt h o s ew h od i e d .
Participants who died before normalization of the pri-
mary study outcome, such as the respiratory rate, con-
tributed person time of observation. Those who died
after the normalization of the primary study outcome,
such as the respiratory rate, were not censored for that
outcome.
We used risk ratios (RR) to measure the association
between case fatality and the intervention. We used
multivariable generalized linear model (GLM) regression
analysis with a log link to estimate the adjusted RR of
the intervention on case fatality.
Initially, we estimated the effect of wasting (WHZ),
percentage oxygen saturation, HIV status, age, relation-
ship with the caretaker and blood culture results on
case fatality in crude analyses. However, only variables
that were associated with case fatality with a P-value <
0.25 or whose addition resulted in a 10% difference in
the parameter estimates, were included in the final mul-
tivariable model.
A cross product term (for HIV status and zinc) was
included in one of the multivariable models to test for
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interaction on the additive scale by estimating homoge-
neity of stratum specific risk differences. Cox propor-
tional hazards models were used to compare time to
normalization of respiratory rate, temperature and oxy-
gen saturation in the two arms.
Ethical issues
Permission to conduct the study was obtained from
Makerere University Faculty of Medicine and Mulago
Hospital Ethics committees.
Results
From September 2006 to March 2007, 475 children
with severe pneumonia were screened for this study.
Of these, 352 were recruited into the study: 176 were
randomized to zinc, while 176 received the placebo
(Figure 1).
Description of study subjects
Of the 352 participants, 198 (56.2%) were male. Age
ranged from 6 to 59 months with a mean of 17.9 (SD
1 2 . 2 )i nt h ez i n cg r o u pa n d1 8 . 1( S D1 1 . 7 )f o rt h ep l a -
cebo group. The rest of the baseline characteristics are
shown in Table 1. Sixty-two (18.1%) children had low
oxygen saturation below 92%. The mean respiratory rate
was 64.7 (SD 15.7), with 65.6 (SD 15.1) in the zinc
group and 63.9 (SD 16.3) in the placebo group.
Laboratory results
The laboratory results included blood slide examina-
tion for malarial parasites, HIV serology and chest
radiographic findings. A total of 311 children were
screened for HIV: 55 (17.7%) were positive; 28/157
(17.8%) in the zinc group and 7/154 (17.5%) in the pla-
cebo group.
Overall, 45/184 (24.5%) of the blood cultures were
positive for bacteria. The bacteria identified included
Streptococcus pneumoniae (14), Staphylococcus aureus
(16), Salmonella species (7), Listeria monocytogenes (3),
Haemophilus influenzae (2) and others (3): that is, Kleb-
siella pneumoniae, Pseudomonas aeruginosa and E.coli.
The rest of the laboratory findings are shown in Table 1.
Outcome measures
Time to normalization of respiratory rate
The median time for normalization of respiratory rate
was 96 hours in the zinc group and 86 hours in the pla-
cebo group. The difference was not statistically signifi-
cant (Table 2).
Time to normalization of temperature
Median time to normalization of the temperature was
18.0 hours in both the zinc and placebo arms (Table 2).
Time to normalization of oxygen saturation
The median time to normalization of oxygen saturation
was 24 hours in the zinc group and 18 hours in the pla-
cebo arm (Table 2).
Duration of hospitalization
Duration of hospitalization was 2.57 days (95% CI 1.72,
3.43) among those who died, and 6.91 (95% CI 6.85,
6.97) for those who survived.
There was no interaction between zinc and HIV status
on the time to normalization of respiratory rate, tem-
perature and oxygen saturation.
Case fatality
Overall case fatality was 28/352 (8.0%): 7/176 (4.0%) in
the zinc and 21/176(11.9%) in the placebo group. Case
fatality was lower in the zinc group: Relative Risk (RR)
0.33 (95% CI of 0.15 to 0.76). When we stratified case
fatality by HIV status, the effect of zinc supplementation
appeared stronger in the HIV infected subgroup.
Among 27 HIV-infected, Highly Active Antiretroviral
Therapy naive children receiving placebo, case fatality was
7/27 (25.9%); versus 0/28 (0%) among HIV infected chil-
dren receiving zinc: RR 0.1 (95% CI 0.0, 1.0). Among 123
HIV uninfected children receiving placebo, case fatality
was 7/127 (5.5%); versus 5/129 (3.9%) among HIV unin-
fected children receiving zinc: RR 0.7 (95% CI 0.2, 2.2).
The Relative Risk Reduction (RRR) was 0.67 (0.24 to
0.85) while the number needed to treat (NNT) was 13.
The excess risk of death attributable to the placebo arm
(Absolute Risk Reduction or ARR) was 8/100 (95% CI:
2/100, 14/100) children. This excess risk was substan-
tially greater among HIV positive children than in HIV
negative children (ARR: 26 (95% CI: 9, 42) per 100 ver-
sus 2 (95% CI: -4, 7) per 100); P-value for homogeneity
of risk differences = 0.006.
Other factors predicting case fatality
HIV-positive children had a higher risk of death compared
to HIV-negative children: RR 2.6 (95% CI 1.0, 6.7). This
increased risk was mostly attributable to the subgroup of
HIV-positive children that received the placebo: RR 4.7
(95% CI 1.8, 12.3) as compared to children that received
the zinc adjunct therapy: RR 0.9 (95% CI 0.1, 7.6).
Children who were hypoxic or malnourished were
more likely to die, compared to HIV-negative or heal-
thier children (Table 3). Girls were two times more
likely to die compared to boys (RR 2.3, 95% CI: 1.1, 4.9).
We found that 3/26 (11.5%) of the patients with posi-
tive blood cultures, and receiving placebo died, while
none of the blood culture positive patients receiving
zinc died. Case fatality among the blood culture negative
patients receiving placebo was 12/64 (18.8%) compared
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receiving zinc.
Adverse drug events
Two children developed vomiting immediately after
receiving the first dose of the intervention: one in the
zinc group and one in the placebo group. Subsequent
doses were tolerated.
Discussion
We carried out a study to determine the effect of zinc as
adjunct therapy on clinical recovery, case fatality and
adverse events in children with severe pneumonia in
Uganda’s national referral hospital. There are two key
findings in this study: overall, zinc supplementation in
these children significantly decreased case fatality, but
did not reduce the time to normalization of the para-
meters for disease severity.
The children who received the placebo were three times
more likely to die as compared to those who received zinc.
The number needed to treat was 13. This means that we
need to treat 13 children with zinc as adjunct therapy to
avert one death. Since the cost of zinc for one child was
630 Ugandan shillings (0.3 USD), we needed 8,190 Ugan-
dan shillings (or 4 USD) to prevent one death. On sub-
group analysis the difference in case fatality attributable to
the protective effect of zinc therapy was greater among
HIV-infected children than among HIV uninfected chil-
dren. This is not surprising since zinc is known to improve
immune response. For example, zinc supplementation
might increase phagocytosis [17] and zinc deficiency pre-
disposes to apoptosis of T lymphocytes in HIV-infected
patients [18]. In fact, it has now been established that zinc
deficiency compromises immunity through a number of
mechanisms, such as T cell dysfunction and dysregulation
of intracellular killing [19].
Screened 
419 
Recovered 155 
Randomized 
352 
Excluded 67: 
Declined consent-30 
Asthma-27 
Cardiac failure-4 
Pneumocystis jirovecii -3 
Not severe pneumonia-3 
 
Zinc- 176 
Analyzed 
Placebo-176 
Analyzed 
Died- 7  Died-21  Recovered 169 
Figure 1 Study profile.
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blood cultures and receiving the placebo died, while
none of the blood culture positive patients receiving
zinc died. Case fatality among the blood culture-nega-
tive patients receiving the placebo was 18.8% compared
to 6.7% of the blood culture-negative patients receiving
zinc. Despite the small numbers, zinc reduced case
fatality regardless of blood culture results. We did not
find a similar study with which to compare our results.
In a related study, Cole and Bose [20] used a CRP of >
40 mg/L as a proxy for bacterial pneumonia. They
found that zinc therapy for children with severe pneu-
monia was associated with prolonged hospitalization.
They, however, did not study the effect of zinc on case
fatality.
Girls were two times more likely to die than boys. The
reason for this is not clear. One study from India found
pneumonia case fatality was about ‘50% higher in girls
than in boys’ [21]. Indeed, excess case fatality rates
among girls has been reported by other workers from
India who speculated that female children are less likely
to be taken for vaccination and medical treatment [22].
Table 1 Baseline characteristics of children admitted with severe pneumonia, Mulago Hospital
Variable Zinc group N = 176 N (%) Placebo group N = 176 N (%)
Sex: Female 78 (44.3) 76 (43.2)
Age in months 6 to 12 76 (43.2) 68 (38.6)
13 to 59 100 (56.8) 108 (61.4)
Mean age (SD) 17.9 (12.2) 18.1 (11.8)
Care taker: Mother 152 (87.4) 163 (94.2)
Other 22 (12.6) 10 (31.3)
Distance: < 5 km 65 (39.4) 70 (41.7)
≥5 km 100 (60.6) 98 (58.3)
Breastfeeding at six months Yes 40 (80.0) 39 (73.6)
No 10 (20.0) 14 (26.4)
Measles vaccination: Yes 103 (83.1) 107 (80.5)
No 21 (16.9) 26 (19.6)
Inability to feed (%) 25 (14.3) 25 (14.2)
Duration of cough in days (IQR) 7.0 (4.0 to 14.0) 7.0 (3.0 to 14.0)
Oxygen saturation (IQR) 95.0 (91.0 to 97.0) 94.0 (90.0 to 98.0)
Oxygen saturation at enrolment < 92% 48 (27.7) 54 (31.4)
≥92% 125 (72.3) 118 (68.6)
Crepitations: Yes 140 (80.0) 147 (84.0)
No 35 (20.0) 28 (16.0)
WHZ <-2SD 30 (17.1) 40 (22.9)
≥-2SD 146 (83.0) 135 (77.1)
HAZ <-2SD 46 (26.1) 44 (25.1)
≥-2SD 130 (73.9) 131 (74.9)
HIV Positive 28 (17.8) 27 (17.5)
Negative 129 (82.2) 127 (82.5)
Malaria (n = 343): Positive 18 (10.5) 19 (11.0)
Negative 153 (89.5) 153 (89.0)
Blood culture: positive 19(20.2) 26(28.9)
negative 75(79.8) 64(71.1)
Zinc in μmol/L (IQR) 4.4 (1.3 to 8.0) 4.8 (2.3 to 10.4)
HAZ, height for age z score; IQR, inter-quartile range; WAZ, weight for age z score
Table 2 Time to normalization of parameters of disease severity, among children with severe pneumonia
Outcome Zinc Placebo
Median (95% CI) Median (95% CI) Hazard ratio (95% CI) P-value
Time to normalization of respiratory rate (hours) 96.0 (83.0, 109.0) 86.0 (75.4, 96.6) 0.88 (0.69, 1.13) 0.306
Time to normalization of temperature (hours) 18.0 (15.1, 20.9) 18.0 (16.0, 20.0) 1.016 (0.79, 1.30) 0.897
Time to normalization of oxygen saturation (hours) 24. 0 (20.6, 27.4) 18.0 (10.6, 25.4) 1.04 (0.74, 1.46) 0.823
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They are lower than those previously reported in Ugan-
dan children [6,7]. The very low zinc levels could be
explained by pre-existing zinc deficiency, redistribution
of zinc to the liver in response to pro-inflammatory
cytokines, and low albumin concentrations [10]. Chil-
dren with zinc deficiency have increased susceptibility to
bacterial disease and are more likely to die [23]. Animal
studies have arrived at similar conclusions [24].
Studies on the effect of zinc supplementation on pneu-
monia have not reported the prevalence of HIV in the
patients studied [10,20]. None the less, the prevalence of
HIV in children in our study was high. In a way our HIV-
infected children with severe pneumonia suffered from a
double disadvantage: HIV related immunodeficiency and
that induced by zinc deficiency.
It appears that initial supplementation with zinc modu-
lates this double disadvantage and significantly reduces
case fatality. However, the ‘modulation’ does not appear
sufficient to shorten recovery from the pneumonia itself in
these HAART naïve, HIV infected children. It is also pos-
sible that zinc increases production of pro-inflammatory
cytokines which would be expected to exacerbate the
situation [25,26]. However, this may not be sufficient to
cancel out the benefit of the zinc on case fatality.
In our study, there was no significant difference in the
measures of clinical improvement between children
receiving the placebo and those receiving zinc, implying
that the zinc might have no appreciable role in shortening
the duration of severe pneumonia even though it signifi-
cantly reduces case fatality. What is clear, though, is that
we have un-earthed a very interesting, yet contradictory
phenomenon, that seems to be related to HIV infection
and severe zinc deficiency. It calls for further studies on
the interaction among HIV, zinc and severe pneumonia.
Hitherto, zinc had only been conclusively linked to
reduction of pneumonia incidence and case fatality
when used for long term supplementation and not as
adjunct therapy [27]. In a study by Brooks et al. in Ban-
gladesh, weekly zinc supplementation for 12 months
reduced the incidence of pneumonia. Of the 14 deaths
in the Bangladeshi placebo group, 10 were pneumonia-
related while there was no pneumonia-related death in
the zinc group [27].
Conditions associated with decreased immunity, such
as malnutrition, partial immunization and HIV infection,
were more likely to be associated with case fatality. For
populations where children are deficient in zinc, severe
prolonged infections deplete the zinc even further and
decrease resistance to infection [28].
Time to normalization of the parameters for disease
severity
The second finding in this study is that zinc supplementa-
tion as adjunct therapy for pneumonia did not reduce the
time to normalization of the parameters for disease sever-
ity. Indeed, the median time for normalization of the
respiratory rate, oxygen saturation and temperature in the
zinc and placebo groups were not significantly different.
This is consistent with results of two Indian and one Aus-
tralian studies [9,29,30].
However, a Bangladesh study demonstrated a signifi-
cant difference in time to normalization of respiratory
rate (40 to 48 hours in the zinc and placebo groups) [8].
Indeed, in a recent study from Nepal, it was shown that
zinc adjunct therapy did not accelerate recovery from
Table 3 Predictors of case fatality among children with severe pneumonia, Mulago Hospital, Uganda
a
Variable RR (Unadjusted) 95% CI RR (adjusted)
b 95% CI RR (adjusted)
c 95% CI
Zinc adjunct therapy 0.3 (0.1,0.8) 0.3 (0.1, 0.97) 0.2 (0.0, 1.1)
WHZ
<-2SD 0.29 (0.1, 0.6) 0.3 (0.1, 0.8) 0.3 (0.1, 0.7)
Oxygen saturation
< 92% 2.4 (1.1, 5.1) 1.6 (0.6, 3.9) 1.4 (0.6, 3.3)
HIV status
Positive 2.7 (1.1, 6.6) 2.6 (1.0, 6.7) 4.3 (1.4, 12.7)
Age
6 to 12 1.0 (0.5, 2.0)
13 to 24 0.1 (0.0, 1.1)
Caretaker relationship to child
Other 0.8 (0.2, 3.2)
Blood culture positive 1.8 (0.6, 6.0)
Zinc adjunct therapy* HIV status
d 5.5 (0.5, 58.3)
a CI, confidence interval
b Only variables with a P-value less than 0.25 in the unadjusted analysis were included in this model.
c Model includes variables with a P-value less than 0.25 and the interaction term for HIV status and Zinc
d Cross-product (interaction) term for HIV status and zinc
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especially of severe pneumonia. So regarding the effect
of zinc on normalization of parameters of disease sever-
ity in severe pneumonia, the jury is still out.
Limitations
There are a few limitations to our study. The median
age at death for children with pneumonia in Uganda is
16 months with an interquartile range of 8 to 23
months according to a study by Kallander [14]. There-
fore, we enrolled children aged 6 to 59 months into the
study, which encompasses this age group. However, one
would expect children below the age of six months to
have the highest risk of case fatality from pneumonia.
So excluding them might have affected our results.
We attempted to get blood culture on most of our
patients but did this on only 184/352 (52.3%) of the
children. Of these, 45/184 (24.5%) were culture positive.
Secondly, we did not measure serum C-reactive protein
(CRP), an acute phase protein. We followed up patients
for only seven days, yet it is possible that a sizeable pro-
portion had pneumonia for a longer period. In the sam-
ple size calculation for case fatality, we arbitrarily chose
an HR of 1.49. As it turns out, this was over ambitious
and represents an over-optimistic effect.
It might have been unrealistic to expect a reduction of
the case fatality from 20% in the placebo group to 9.3%
in the zinc group. In the calculation of the sample size,
we assumed a case fatality of 20% in the placebo group.
This was based on results of previous studies by our
team [12] where we demonstrated a case fatality of 20%
in children with severe pneumonia. Another one of our
studies showed a case fatality of 15.5% among children
with severe pneumonia in the same hospital [31].
Of course, these are high case fatalities but were not
un-expected, especially since the children were ill with
malnutrition and/or HIV.
In our study, 20/351 (4.5%) children died before achiev-
ing normalization of the respiratory rate, temperature
and oxygen saturation (the numbers and proportions are
much smaller when each of these outcomes is considered
independently) and were thus lost to follow-up. This loss
may have caused bias but, because the loss was minimal,
it is unlikely to have been large enough to alter the
results significantly. Indeed, these high case fatalities
reflect the importance of pneumonia as a cause of child
deaths in the community.
In a recent study, Kallander and others in the Iganga
Demographic Study Site in eastern Uganda found that
pneumonia accounted for 27% of child deaths [14]. We
are heartened that the overall case fatality in the current
study was only 28/352 (8.0%), dropping to 4.0% in the
zinc supplemented group.
Unlike a similar study, which followed up patients for
two weeks [10], we followed up patients for a maximum
of seven days based on our experience of severe pneu-
monia patients most of whom spend less than seven
days [2,31] in the hospital. The relatively short time of
follow-up might have reduced our power to detect a dif-
ference in the duration of hospitalization.
Conclusion
Zinc adjunct therapy for severe pneumonia had no signifi-
cant effect on time to normalization of the respiratory
rate, temperature and oxygen saturation. However, zinc
supplementation in these children significantly decreased
case fatality. The difference in case fatality attributable to
the protective effect of zinc therapy was greater among
HIV-infected than among HIV-uninfected children. Given
these results, zinc could be considered for use as adjunct
therapy for severe pneumonia, especially among HAART
naïve, HIV-infected children in our environment.
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